Patent: 8,734,813
✉ Email this page to a colleague
Summary for Patent: 8,734,813
| Title: | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| Abstract: | The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults. |
| Inventor(s): | Robert P. Ryall |
| Assignee: | Sanofi Pasteur Inc |
| Application Number: | US13/843,037 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,734,813
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Sanofi Vaccines Us Inc. | MENACTRA | meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine | For Injection | 125089 | January 14, 2005 | 8,734,813 | 2033-03-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,734,813
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| African Regional IP Organization (ARIPO) | 1897 | ⤷ Start Trial |
| Australia | 2007216743 | ⤷ Start Trial |
| Australia | 2010219288 | ⤷ Start Trial |
| Belgium | 2012C050 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
